Abstract
Background: Fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) is superior to angiography-guided PCI. The clinical uptake of FFR has been limited, however, by the need to advance a wire in the coronary artery, the additional time required and the need for hyperaemic agents which can cause patient discomfort. FFR derived from routine coronary angiography eliminates these issues. Aims: The aim of this study was to assess the diagnostic performance and accuracy of three-dimensional quantitative coronary angiography (3D-QCA)-based vessel FFR (vFFR) compared to pressure wire-based FFR (≤0.80). Methods: The FAST II (Fast Assessment of STenosis severity) study was a prospective observational multicentre study designed to evaluate the diagnostic accuracy of vFFR compared to the reference standard (pressure wire-based FFR ≤0.80). A total of 334 patients from six centres were enrolled. Both site-determined and blinded independent core lab vFFR measurements were compared to FFR. Results: The core lab vFFR was 0.83±0.09 and pressure wire-based FFR 0.83±0.08. A good correlation was found between core lab vFFR and pressure wire-based FFR (R=0.74; p<0.001; mean bias 0.0029±0.0642). vFFR had an excellent diagnostic accuracy in identifying lesions with an invasive wire-based FFR ≤0.80 (area under the curve [AUC] 0.93; 95% confidence interval [CI]: 0.90-0.96; p<0.001). Positive predictive value, negative predictive value, diagnostic accuracy, sensitivity and specificity of vFFR were 90%, 90%, 90%, 81% and 95%, respectively. Conclusions: 3D-QCA-based vFFR has excellent diagnostic performance to detect FFR ≤0.80.
| Original language | English |
|---|---|
| Pages (from-to) | 1498-1505 |
| Number of pages | 8 |
| Journal | EuroIntervention |
| Volume | 17 |
| Issue number | 18 |
| DOIs | |
| Publication status | Published - Apr 2022 |
Bibliographical note
Funding Information: Z. Ali received grants from Abbott Vascular, Cardiovascular Systems Inc., personal fees from Amgen, AstraZeneca and Boston Scientific, and equity from Shockwave Medical, outside the submitted work. N. Van Mieghem received research grant support from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Medtronic, PulseCath BV, Abiomed, Daiichi Sankyo, and Pie Medical. J. Daemen received institutional grant/research support from AstraZeneca, Abbott Vascular, Boston Scientific, ACIST Medical, Medtronic, MicroPort, Pie Medical, and ReCor Medical. N. Tanaka serves as a consultant for Abbott Medical Japan, Kaneka Medix, and Boston Scientific Japan. The other authors have no conflicts of interest to declare.Publisher Copyright: © Europa Digital & Publishing 2022. All rights reserved.